Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer–the Experience of a Tertiary Cancer Center

Background: Colorectal cancer (CRC) is the third most common cancer in Europe, with an annual increase in incidence ranging between 0.4 and 3.6% in various countries. Although the development of CRC was extensively studied, limited number of new therapies were developed in the last few years. Bevaci...

Descripción completa

Detalles Bibliográficos
Autores principales: Căinap, Călin, Bochiş, Ovidiu-Vasile, Vlad, Cătălin, Popita, Raluca, Achimaş-Cadariu, Patriciu, Havasi, Andrei, Vidrean, Andreea, Dranca, Alexandra, Piciu, Andra, Constantin, Anne-Marie, Tat, Tiberiu, Dana, Maniu, Crişan, Ovidiu, Cioban, Cosmin Vasile, Bălăcescu, Ovidiu, Coza, Ovidiu, Bălăcescu, Loredana, Marta, Monica Mihaela, Bota, Madalina, Căinap, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991840/
https://www.ncbi.nlm.nih.gov/pubmed/33776758
http://dx.doi.org/10.3389/fphar.2021.487316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991840/
https://www.ncbi.nlm.nih.gov/pubmed/33776758
http://dx.doi.org/10.3389/fphar.2021.487316

Ejemplares similares